nach oben

Erschienen in:

16.07.2021 | Review

B3Pdb: an archive of blood–brain barrier-penetrating peptides

verfasst von: Vinod Kumar, Sumeet Patiyal, Rajesh Kumar, Sukriti Sahai, Dilraj Kaur, Anjali Lathwal, Gajendra P. S. Raghava

Erschienen in: Brain Structure and Function | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

The blood–brain barrier poses major hurdles in the treatment of brain-related ailments. Over the past decade, interest in peptides-based therapeutics has thrived a lot because of their higher benefit to risk ratio. However, a complete knowledgebase providing a well-annotated picture of the peptide as a therapeutic molecule to cure brain-related ailments is lacking. We have built up a knowledgebase B3Pdb on blood–brain barrier (BBB)-penetrating peptides in the present study. The B3Pdb holds clinically relevant experimental information on 1225 BBB-penetrating peptides, including mode of delivery, animal model, in vitro/in vivo experiments, chemical modifications, length. Hoping that drug delivery systems can improve central nervous system disorder-related therapeutics. In this regard, B3Pdb is an important resource to support the rational design of therapeutics peptides for CNS-related disorders. The complete ready-to-use and updated database with a user-friendly web interface is available to the scientific community at https://webs.iiitd.edu.in/raghava/b3pdb/.

Almeida CR, Serra T, Oliveira MI et al (2014) Impact of 3-D printed PLA- and chitosan-based scaffolds on human monocyte/macrophage responses: Unraveling the effect of 3-D structures on inflammation. Acta Biomater 10:613–622. https://doi.org/10.1016/j.actbio.2013.10.035CrossRefPubMed

Alvarez-Erviti L, Seow Y, Yin H et al (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341–345. https://doi.org/10.1038/nbt.1807CrossRefPubMed

Bertrand Y, Currie JC, Poirier J et al (2011) Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer 105:1697–1707. https://doi.org/10.1038/bjc.2011.427CrossRefPubMedPubMedCentral

Caillé I, Allinquant B, Dupont E et al (2004) Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131:2173–2181. https://doi.org/10.1242/dev.01103CrossRefPubMed

Ché C, Yang G, Thiot C et al (2010) New angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem 53:2814–2824. https://doi.org/10.1021/jm9016637CrossRefPubMed

De Boer AG, Gaillard PJ (2007) Drug targeting to the brain. Annu Rev Pharmacol Toxicol 47:323–355CrossRef

Demeule M, Currie JC, Bertrand Y et al (2008a) Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem 106:1534–1544. https://doi.org/10.1111/j.1471-4159.2008.05492.xCrossRefPubMed

Demeule M, Regina A, Ché C et al (2008b) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324:1064–1072. https://doi.org/10.1124/jpet.107.131318CrossRefPubMed

Dong X (2018) Current strategies for brain drug delivery. Theranostics 8:1481–1493CrossRef

Drin G, Cottin S, Blanc E, Rees AR, Temsamani J (2003) Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278(33):31192–31201. https://doi.org/10.1074/jbc.M303938200CrossRefPubMed

Gaillard PJ, Appeldoorn CCM, Rip J et al (2012) Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. In: Journal of Controlled Release. pp 364–369

Gustavsson A, Svensson M, Jacobi F et al (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:718–779. https://doi.org/10.1016/j.euroneuro.2011.08.008CrossRefPubMed

Hwang DW, Son S, Jang J, Youn H, Lee S, Lee D, Lee Y-S, Jeong JM, Kim WJ, Lee DS (2011) A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 32(21):4968–4975. https://doi.org/10.1016/j.biomaterials.2011.03.047CrossRefPubMed

Ke W, Shao K, Huang R et al (2009) Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30:6976–6985. https://doi.org/10.1016/j.biomaterials.2009.08.049CrossRefPubMed

Kumar P, Wu H, McBride JL et al (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39–43. https://doi.org/10.1038/nature05901CrossRefPubMed

Kurzrock R, Gabrail N, Chandhasin C et al (2012) Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11:308–316. https://doi.org/10.1158/1535-7163.MCT-11-0566CrossRefPubMed

Lathwal A, Kumar R, Raghava GPS (2020a) OvirusTdb: A database of oncolytic viruses for the advancement of therapeutics in cancer. Virology 548:109–116. https://doi.org/10.1016/j.virol.2020.05.016CrossRefPubMed

Lathwal A, Kumar R, Raghava GPS (2020b) Computer-aided designing of oncolytic viruses for overcoming translational challenges of cancer immunotherapy. Drug Discov Today 25:1198–1205CrossRef

Lo SL, Wang S (2008) An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 29:2408–2414. https://doi.org/10.1016/j.biomaterials.2008.01.031CrossRefPubMed

Malakoutikhah M, Teixidó M, Giralt E (2011) Shuttle-mediated drug delivery to the brain. Angew Chemie Int Ed 50:7998–8014CrossRef

Nagpal K, Singh SK, Mishra DN (2013) Drug targeting to brain: A systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. Expert Opin Drug Deliv 10:927–955CrossRef

Neuwelt E, Abbott NJ, Abrey L et al (2008) Strategies to advance translational research into brain barriers. Lancet Neurol 7:84–96CrossRef

Oller-Salvia B, Sánchez-Navarro M, Giralt E, Teixidó M (2016) Blood-brain barrier shuttle peptides: An emerging paradigm for brain delivery. Chem Soc Rev 45:4690–4707CrossRef

Pankevich DE, Altevogt BM, Dunlop J et al (2014) Improving and accelerating drug development for nervous system disorders. Neuron 84:546–553CrossRef

Pardridge WM (1998) CNS drug design based on principles of blood-brain barrier transport. J Neurochem 70:1781–1792CrossRef

Pardridge WM (2012) Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 32:1959–1972CrossRef

Prades R, Guerrero S, Araya E et al (2012) Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials 33:7194–7205. https://doi.org/10.1016/j.biomaterials.2012.06.063CrossRefPubMed

Ren J, Shen S, Wang D et al (2012) The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33:3324–3333. https://doi.org/10.1016/j.biomaterials.2012.01.025CrossRefPubMed

Ronaldson PT, Persidsky Y, Bendayan R (2008) Regulation of ABC membrane transporters in glial cells: Relevance to the pharmacotherapy of brain HIV-1 infection. Glia 56:1711–1735. https://doi.org/10.1002/glia.20725CrossRefPubMed

Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285:1569–1572. https://doi.org/10.1126/science.285.5433.1569CrossRefPubMed

Van Dorpe S, Bronselaer A, Nielandt J et al (2012) Brainpeps: The blood-brain barrier peptide database. Brain Struct Funct 217:687–718CrossRef

Vizioli NM, Rusell ML, Carbajal ML et al (2005) On-line affinity selection of histidine-containing peptides using a polymeric monolithic support for capillary electrophoresis. Electrophoresis 26:2942–2948. https://doi.org/10.1002/elps.200410416CrossRefPubMed

Wang D, El-Amouri SS, Dai M et al (2013) Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci U S A 110:2999–3004. https://doi.org/10.1073/pnas.1222742110CrossRefPubMedPubMedCentral

Wong HL, Wu XY, Bendayan R (2012) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64:686–700CrossRef

Xiang L, Zhou R, Fu A et al (2011) Targeted delivery of large fusion protein into hippocampal neurons by systemic administration. J Drug Target 19:632–636. https://doi.org/10.3109/1061186X.2010.523788CrossRefPubMed

Yan H, Wang L, Wang J et al (2012) Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano 6:410–420. https://doi.org/10.1021/nn203749vCrossRefPubMed

Titel: B3Pdb: an archive of blood–brain barrier-penetrating peptides
verfasst von: Vinod Kumar
Sumeet Patiyal
Rajesh Kumar
Sukriti Sahai
Dilraj Kaur
Anjali Lathwal
Gajendra P. S. Raghava
Publikationsdatum: 16.07.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Brain Structure and Function / Ausgabe 8/2021
Print ISSN: 1863-2653
Elektronische ISSN: 1863-2661
DOI: https://doi.org/10.1007/s00429-021-02341-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Neurodevelopmental scaling is a major driver of brain–behavior differences in temperament across dog breeds

A quantitative analysis of cerebellar anatomy in birds

Structural properties of corpus callosum are associated differently with verbal creativity and visual creativity

The effect of the PARK16 rs11240572 variant on brain structure in Parkinson's disease

Prevalence of the interthalamic adhesion in the human brain: a review of literature

In vivo restricted diffusion imaging (RDI) is sensitive to differences in axonal density in typical children and adults